Early Trials: Johnson & Johnson COVID Vaccine Prompts Immune Response
Interactive Video
•
Health Sciences, Biology
•
University
•
Hard
Wayground Content
FREE Resource
The Johnson & Johnson vaccine, using an adenovirus to deliver the coronavirus spike protein, has shown promising results in early clinical trials. It generates an immune response in both young and elderly volunteers, with 90% producing antibodies within 29 days. The vaccine is advantageous due to its single-dose nature and less stringent storage requirements compared to Pfizer and Moderna vaccines. Phase 3 trials will provide more insights, and J&J plans to seek FDA emergency approval soon.
Read more
1 questions
Show all answers
1.
OPEN ENDED QUESTION
3 mins • 1 pt
What new insight or understanding did you gain from this video?
Evaluate responses using AI:
OFF
Access all questions and much more by creating a free account
Create resources
Host any resource
Get auto-graded reports
Continue with Google
Continue with Email
Continue with Classlink
Continue with Clever
or continue with
Microsoft
%20(1).png)
Apple
Others
Already have an account?
